Drug Profile
BLI 489
Alternative Names: BLI-489Latest Information Update: 15 Aug 2021
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antibacterials; Penems; Small molecules
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Urinary tract infections
Most Recent Events
- 20 Jun 2021 Antimicrobial data from preclinical studies presented at the World Microbe Forum 2021
- 13 Apr 2019 Pharmacodynamics data from a preclinical study in Pneumonia presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2019)
- 29 Sep 2011 No development reported - Phase-I for Bacterial infections in Japan (IV)